Volume 25, Number 9—September 2019
Synopsis
Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum
Pornboonya Nookeu, Nasikarn Angkasekwinai, Suporn Foongladda, and Pakpoom Phoompoung
Table
Clinical characteristics and treatment for 21 patients infected with Mycobacterium haemophilum Bangkok, Thailand*
| Patient no. | Age, y/sex | Disease or condition, CD4 cell count/mm3 | Clinical manifestation | Site of positive culture | Surgical treatment | Drug treatment | Treatment duration, mo† | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 |
25/F |
AIDS, 17 |
Brain abscesses, septicemia |
Blood |
None |
AZM, LVX, EMB |
1 |
Died |
| 2 |
35/F |
AIDS, 12 |
Brain abscesses |
Brain tissue |
None |
NA |
NA |
Lost to follow-up |
| 3 |
35F |
AIDS, 40 |
Myelitis |
Spinal cord tissue |
None |
INH, RIF, PZA, EMB, CLR, AMK |
2 |
Treatment failure |
| 4 |
29/M |
AIDS, 14 |
Skin nodule (left popliteal fossa) |
Skin |
None |
AZM, LVX, RIF |
NA |
Lost to follow-up |
| 5 |
52/M |
AIDS, 6 |
Plague (right hand) |
Skin |
None |
CLR, CIP, RIF |
6 |
Cured |
| 6 |
46/F |
AIDS, 190 |
Chronic ulcer (left foot) |
Pus |
None |
MFX |
3 |
Cured |
| 7 |
36/F |
AIDS, 12 |
Auricular abscess |
Pus |
None |
AZM, LVX, RIF |
12 |
Cured |
| 8 |
53/F |
HIV+, 657 |
Preauricular abscess |
Pus |
I and D |
CLR, CIP |
12 |
Cured |
| 9 |
25/F |
SLE |
Chronic wound and osteomyelitis (right ankle), olecranon bursitis |
Bone |
Debridement |
IMI, AMK; then AZM, CIP, RIF |
6 (1.5/4.5) |
Relapsed |
| 10 |
39/F |
SLE |
Tenosynovitis (right index finger) |
Pus |
Debridement |
AMK; then CLR, LVX |
6 (2/4) |
Cured |
| 11 |
57/F |
SLE |
Skin nodules (both elbows) |
Skin |
None |
CLR, CIP, RIF |
6 |
Cured |
| 12 |
47/F |
SLE, dermatomyositis |
Skin nodules (both elbows) |
Skin |
None |
IMI, AMK; then AZM, CIP, RIF |
6 (0.5/5.5) |
Cured |
| 13 |
39/F |
SLE, DM |
Skin abscess (right ankle) |
Pus |
I and D |
AMK; then CLR, LVX, DCS |
12 (2/10) |
Cured |
| 14 |
69/M |
IFN-γ autoantibody |
Septicemia, spondylodiscitis |
Blood |
None |
CLR, LVX, RIF |
24 |
Relapsed |
| 15 |
73/F |
IFN-γ autoantibody |
Lymphadenitis (right cervical node) |
Lymph node |
None |
IMI, CLR; then CLR, CIP, SXT |
12 |
Cured |
| 16 |
60/F |
Kidney transplant |
Skin nodules (both arms/legs), septic arthritis (right ankle) |
Pus |
Debridement |
AMK, CLR, LVX, LZD; then MFX, AZM, RIF, LZD |
11 (1/10) |
Improved |
| 17 |
58/F |
Kidney transplant |
Plague (both legs) |
Skin |
None |
IMI, AMK, CLR; then AZM, LVX, RIF |
12 (1/11) |
Relapsed |
| 18 |
65/F |
DM,
A1C 6.7% |
Scleritis and keratitis |
Sclera |
Enucleation |
IMI, CLR, LVX, RIF, LZD |
4 |
Treatment failure |
| 19 |
65/M |
DM,
A1C 13.3% |
Endophthalmitis |
Vitreous fluid |
None |
IMI, AMK, LVX; then AZM, RIF, DOX |
12 (0.5/11.5) |
Cured |
| 20 |
53/M |
Ankylosing spondylitis |
Skin nodules (right elbow) |
Skin |
Surgical excision |
CLR, LVX |
6 |
Treatment failure |
| 21 | 48/M | Nephrotic syndrome | Skin nodules (right elbow) | Skin | None | CLR, CIP, RIF | 12 | Cured |
*AMK, amikacin; AZM, azithromycin; A1C, hemoglobin A1C; CIP, ciprofloxacin; CLR, clarithromycin; DCS,
†Values in parentheses are durations for each drug group.
Page created: August 21, 2019
Page updated: August 21, 2019
Page reviewed: August 21, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.